2025 Q3 -tulosraportti
68 päivää sitten2,25 DKK/osake
Viimeisin osinko
1,47 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
222 827
Myynti
Määrä
220 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 511 | DDB | DDB | ||
| 1 671 | - | - | ||
| 386 | - | - | ||
| 11 | - | - | ||
| 100 | - | - |
Ylin
425,3VWAP
Alin
414VaihtoMäärä
199,6 479 460
VWAP
Ylin
425,3Alin
414VaihtoMäärä
199,6 479 460
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenA very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·17 t sittenAfter seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.
·13 t sittenYou will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.
·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?- ·21.12.2025I don't understand how the stock price of Novonesis can be higher than Novo Nordisk ?
·2.1.There are 2 companies that have nothing to do with each other! One makes medicine and the other makes enzymes for food and detergents 🤗 The only thing that connects them is the first 4 letters “Novo” - ·11.12.2025So I bought a little
·16.12.2025The trigger is Peanut allergy, something the US Market values if Novonesis succeeds! It's not Blockbuster, it's Blockbuster+ :)
·18.12.2025Your side remarks, "if Novonesis succeeds" do point to there being a bit of gambling involved with this trigger. Because it could also be that they don't succeed. I mostly held that it was the biofuel part that should drive growth, because it was at 25% in this part of the business, but it seems the stock isn't really valued by investors, and it is somewhat volatile with a peak around 475 and a bottom around 375, and even though it's trending upwards, it's a rather flat growth curve. I think I'll exit next time it hits 475, and find something else and more fun to invest in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
68 päivää sitten2,25 DKK/osake
Viimeisin osinko
1,47 %Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenA very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·17 t sittenAfter seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.·13 t sittenYou will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.
- ·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?
- ·21.12.2025I don't understand how the stock price of Novonesis can be higher than Novo Nordisk ?·2.1.There are 2 companies that have nothing to do with each other! One makes medicine and the other makes enzymes for food and detergents 🤗 The only thing that connects them is the first 4 letters “Novo”
- ·11.12.2025So I bought a little·16.12.2025The trigger is Peanut allergy, something the US Market values if Novonesis succeeds! It's not Blockbuster, it's Blockbuster+ :)·18.12.2025Your side remarks, "if Novonesis succeeds" do point to there being a bit of gambling involved with this trigger. Because it could also be that they don't succeed. I mostly held that it was the biofuel part that should drive growth, because it was at 25% in this part of the business, but it seems the stock isn't really valued by investors, and it is somewhat volatile with a peak around 475 and a bottom around 375, and even though it's trending upwards, it's a rather flat growth curve. I think I'll exit next time it hits 475, and find something else and more fun to invest in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
222 827
Myynti
Määrä
220 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 511 | DDB | DDB | ||
| 1 671 | - | - | ||
| 386 | - | - | ||
| 11 | - | - | ||
| 100 | - | - |
Ylin
425,3VWAP
Alin
414VaihtoMäärä
199,6 479 460
VWAP
Ylin
425,3Alin
414VaihtoMäärä
199,6 479 460
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
68 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 25.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 3.4.2025 | |
| 2024 Q4 -tulosraportti | 26.2.2025 |
Datan lähde: Quartr, FactSet
2,25 DKK/osake
Viimeisin osinko
1,47 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenA very high PE. I can see that PE is expected to fall going forward, but still high given that Novonesis, as far as I can see, has neither unique products, processes, nor sales channels·17 t sittenAfter seeing how analysts missed the mark on Novo Nordisk's share price, I take those price targets with a large grain of salt. Furthermore, Novonesis has been talked up for several years, without there yet having been a gain from buying them. So I think, with that PE and with that history, there is reason to be cautious.·13 t sittenYou will probably need to provide a bit more information for your views to actually make sense. You write that PE is high, but you can clearly see that it will be falling going forward. Why? They don't have any unique products? Have you seen the presentation from January 8 (slide 10 possibly). Do you have a grasp of their product portfolio? Analysts are never wrong until the opposite is proven. Analysts base their assessments on different scenarios, and it is your own task to decide whether you agree with these scenarios or not. Analysts continuously adjust their estimates as the market changes and more things become transparent.
- ·22.12.2025Quite a price-wise "desert walk" over the last 10 years. Even the miserable C25 has done better in 2025. I would say 10 years is long-term, so--- Is there anything imminent that can make the stock more interesting?
- ·21.12.2025I don't understand how the stock price of Novonesis can be higher than Novo Nordisk ?·2.1.There are 2 companies that have nothing to do with each other! One makes medicine and the other makes enzymes for food and detergents 🤗 The only thing that connects them is the first 4 letters “Novo”
- ·11.12.2025So I bought a little·16.12.2025The trigger is Peanut allergy, something the US Market values if Novonesis succeeds! It's not Blockbuster, it's Blockbuster+ :)·18.12.2025Your side remarks, "if Novonesis succeeds" do point to there being a bit of gambling involved with this trigger. Because it could also be that they don't succeed. I mostly held that it was the biofuel part that should drive growth, because it was at 25% in this part of the business, but it seems the stock isn't really valued by investors, and it is somewhat volatile with a peak around 475 and a bottom around 375, and even though it's trending upwards, it's a rather flat growth curve. I think I'll exit next time it hits 475, and find something else and more fun to invest in.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
222 827
Myynti
Määrä
220 396
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 35 511 | DDB | DDB | ||
| 1 671 | - | - | ||
| 386 | - | - | ||
| 11 | - | - | ||
| 100 | - | - |
Ylin
425,3VWAP
Alin
414VaihtoMäärä
199,6 479 460
VWAP
Ylin
425,3Alin
414VaihtoMäärä
199,6 479 460
Välittäjätilasto
Dataa ei löytynyt